These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1440849)

  • 1. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.
    Appelbaum FR; Matthews DC; Eary JF; Badger CC; Kellogg M; Press OW; Martin PJ; Fisher DR; Nelp WB; Thomas ED
    Transplantation; 1992 Nov; 54(5):829-33. PubMed ID: 1440849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
    Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW
    Blood; 1995 Feb; 85(4):1122-31. PubMed ID: 7849300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
    Matthews DC
    Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
    Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
    Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
    Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
    Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-targeted therapy for myeloid leukemia.
    Appelbaum FR
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.
    Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Hui TE; Martin PJ; Mitchell D; Press OW; Storb R; Bernstein ID
    Blood; 1999 Aug; 94(4):1237-47. PubMed ID: 10438711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
    Caron PC; Dumont L; Scheinberg DA
    Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.
    Schwartz MA; Lovett DR; Redner A; Finn RD; Graham MC; Divgi CR; Dantis L; Gee TS; Andreeff M; Old LJ
    J Clin Oncol; 1993 Feb; 11(2):294-303. PubMed ID: 8426207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
    Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates.
    Sievers EL
    Curr Opin Oncol; 2000 Jan; 12(1):30-5. PubMed ID: 10687726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
    Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
    Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
    Caron PC; Scheinberg DA
    Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model.
    van der Jagt RH; Badger CC; Appelbaum FR; Press OW; Matthews DC; Eary JF; Krohn KA; Bernstein ID
    Cancer Res; 1992 Jan; 52(1):89-94. PubMed ID: 1530769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
    Press OW; Eary JF; Appelbaum FR; Martin PJ; Badger CC; Nelp WB; Glenn S; Butchko G; Fisher D; Porter B
    N Engl J Med; 1993 Oct; 329(17):1219-24. PubMed ID: 7692295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
    Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
    Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
    Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
    Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.